Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment ; volume:11 ; number:1 ; day:28 ; month:1 ; year:2021 ; pages:1-10 ; date:12.2021
Scientific reports ; 11, Heft 1 (28.1.2021), 1-10, 12.2021
- Creator
-
Gao, Bowen
Chen, Jiongyu
Han, Bingchen
Zhang, Xinfeng
Hao, Jijun
Giuliano, Armando E.
Cui, Yukun
Cui, Xiaojiang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-021-82128-0
- URN
-
urn:nbn:de:101:1-2021031417583403962153
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gao, Bowen
- Chen, Jiongyu
- Han, Bingchen
- Zhang, Xinfeng
- Hao, Jijun
- Giuliano, Armando E.
- Cui, Yukun
- Cui, Xiaojiang
- SpringerLink (Online service)
Other Objects (12)
Ceritinib is a novel triple negative breast cancer therapeutic agent
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Therapeutic landscape in mutational triple negative breast cancer
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Andrographolide as a therapeutic agent against breast and ovarian cancers
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Ceritinib is a novel triple negative breast cancer therapeutic agent
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Therapeutic landscape in mutational triple negative breast cancer
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Andrographolide as a therapeutic agent against breast and ovarian cancers
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Ceritinib is a novel triple negative breast cancer therapeutic agent
Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer
Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
Therapeutic landscape in mutational triple negative breast cancer
Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
Therapeutic potential of PLK1 inhibition in triple-negative breast cancer
Recent advances in therapeutic strategies for triple-negative breast cancer
Comparative study of triple-negative breast cancer lines to selected therapeutic treatments
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer
Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities
Andrographolide as a therapeutic agent against breast and ovarian cancers